Please see new article by SuviCa scientists and advisory board members titled “Bouvardin is a Radiation Modulator with a Novel Mechanism of Action” (Stickel SA, et al. Radiat Res. 2015): http://www.ncbi.nlm.nih.gov/pubmed/26414509.
January, 2015: Congratulations to Drs. Raben and Jimeno who are co-author and senior author, respectively, on an article in Clinical Cancer Research that describes a Phase 1 study of a multi-target inhibitor in combination with chemo-radiation in patients with head and neck cancer. More information at http://www.ncbi.nlm.nih.gov/pubmed/25573383.
September 24th, 2013: SuviCa, Inc., a private cancer drug discovery and development company that applies its proprietary screen to identify small molecule anticancer agents, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 contract from the National Cancer Institute (NCI). Through the terms of the contract, SuviCa will discover […]
SuviCa is pleased to announce that it has been selected to present at the Rocky Mountain Life Science Investor & Partnering Conference to be held September 18-19 at the Ritz-Carlton Hotel in Denver, Colorado. For full story see: http://www.cobioscience.com/news-1/presenting-companies-announced.
SuviCa advisor on preclinical pharmacology, Dr. Daniel Gustafson, named CSU Shipley University Chair in Comparative Oncology. For full story see: http://www.today.colostate.edu.
November Focus 2012 PDF
Colorado BioScience Association
NY Venture Summit 2012
https://www.cu.edu/techtransfer/media/newsreleases/2012/BDEG_CO_2012.html
Colorado Biz Magazine PDF